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two back translations of the English ItchRO. Cognitive interviews with five children 
with ALGS (patient report) and five parents (observer report) were to be performed. 
Key inclusion criteria were: children aged 5-9 years with cholestatic liver disease 
(ALGS) or progressive familial intrahepatic cholestasis (PFIC), who were also expe-
riencing itching. Results: Recruitment was challenging and threatened to delay 
the clinical trial programme. Thus, recruitment was extended to include children 
who were 3-17 years of age, and in Spain and Germany, patients with alternative 
pathologies that manifested primarily with generalized pruritus were included. The 
final sample included: 15 with ALGS (France n= 5; Poland n= 5; Germany n= 3; Spain 
n= 2), 2 with PFIC (Spain), 2 with atopic dermatitis (Germany) and 1 with contact 
dermatitis (Spain). The ItchRO translations were well understood; there were no 
apparent differences in translation interpretations by disease state. ConClusions: 
Recruitment in linguistic validation projects in rare diseases can be a hurdle, yet 
patient understanding, rather than those of ‘lay people, ’ is preferable in paediatrics 
to ensure adequate interpretation, which can vary substantially across children. As a 
result patients with similar symptom and impact characteristics could be recruited 
if recruiting the primary population is likely to delay clinical trial research in rare 
diseases, where there is an urgent need for treatment.
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objeCtives: To determine NutriQoL® responsiveness and minimal clinically impor-
tant difference (MCID) in patients receiving HEN. Methods: NutriQoL®, a specific 
questionnaire, developed and validated in Spain, for the assessment of HRQoL in 
patients receiving HEN regardless of the underlying condition was administered 
to a prospective cohort from 4 Spanish hospitals. It includes 17 pairs of items of 
HEN-related HRQoL, scoring from -51 (worst HRQoL) to 51 (best HRQoL). NutriQoL® 
was completed three times within 1-month (±15 days) intervals (visit 1/visit 2/visit 
3). Responsiveness was assessed by estimating the effect size and the standard-
ized response mean between visits 1 and 3. For MCID calculation an anchor-based 
approach was performed. Interquartile range of the change in NutriQoL® from 
patients, who reported changes in their health-status (worse or better) between 
visits 2 and 3, was used. Results: A total of 86 subjects who presented clinical 
changes between visits [63% male; mean (SD) age 61 (13)] participated. Cancer was 
the main diagnosis leading to HEN prescription (66.3%). NutriQoL® scores were 16.98 
(14.57), 16.63 (14.86) and 18.92 (15.25) for visit 1, 2 and 3, respectively. Up to 78.79% of 
patients reported improvements in their HRQoL since the introduction of HEN. The 
estimated effect size and the standardized mean response between visit 1 and 3 
were 0.23 and 0.24. Regarding MCID, NutriQoL® total scores difference between visit 
2 and 3 in those patients that perceived changes in their health status was between 
-3.75 and 4.25 (interquartile range). ConClusions: NutriQoL® responsiveness is 
moderate. This may be due to the limited temporal period between visits since most 
of patients referred improvements in their condition. A difference of ±4 points on 
NutriQoL® total score regarding a previous administration demonstrates a clinical 
change that affects patients HRQoL.
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objeCtives: Treatment effects on health-related quality of life (QoL) often differ 
depending on whether they are measured prospectively (before and after treatment) 
or retrospectively (after treatment only). It is not clear which of either evaluations is 
more valid: Prospective evaluations may be biased by scale recalibration (a changed 
understanding of the response scale), and retrospective evaluations may be biased 
by recall bias (a wrong assessment of former QoL). Methods: Based on an analy-
sis of literature, we present an overview on (a) possible biases in prospective and 
retrospective measurement of QoL, (b) how these biases are named and defined in 
literature, and (c) current approaches to distinguish scale recalibration and recall 
bias. Results: The definitions of different biases are inconsistent. Many authors 
do not clearly distinguish measurement bias from true change. Furthermore, some 
consider only scale recalibration or only recall bias. There are different approaches 
for distinguishing scale recalibration and recall bias. We argue that these make too 
extensive assumptions to be valid. ConClusions: Much of the current discussion 
on the validity of prospective and retrospective QoL measurement suffers from 
unclear definitions, especially of “response shift” and “recall bias”, or from neglect-
ing one of the possible biases. We suggest more elaborate definitions for different 
types of bias, and recommend taking both kinds of bias into consideration when 
measuring change in QoL. Due to a lack of valid methods, there is not enough evi-
dence on the extent of these biases yet; therefore the best approach for outcomes 
studies might be to include both prospective and retrospective assessments. In the 
long run, valid methods need to be developed to determine the most valid method 
of QoL assessment.
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The patients are asked to complete the questionnaire at initial contact with the out-
patient clinic and at four follow-up time points; one week, and one, three, and twelve 
months post-fracture). The last inclusion date will be December 31st2014. Results: 
The hypothesis is that the QUALIOST will provide a better estimate of the impact 
of osteoporosis-related fractures on HRQoL as it contains disease-relevant aspects, 
which may not be sufficiently covered in the generic EQ-5D-5L questionnaire. We will 
develop a mapping algorithm to predict EQ-5D derived utilities for Danish fracture 
patients from the QUALIOST, which can be used in future studies, where utilities then 
may be estimated from QUALIOST results. ConClusions: Mapping from QUALIOST 
scores to EQ-5D-5L derived utilities will enable estimation of preference-based HRQoL 
utilities for patients with osteoporotic fractures.
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objeCtives: Diabetic macular edema (DME) is a serious condition occurring in 
patients with diabetic retinopathy (DR) which is a common complication of diabetes. 
Understanding not only objective measurements such as visual acuity, but also the 
patients’ perspective is important in gaining a comprehensive understanding of 
the impact of DME and its treatment on their functioning and well-being. The aim 
of this study is to understand possible measurements to investigate the impact of 
DME on health-related quality of life (HRQoL), by identifying currently available 
measurements, their ability to differentiate between DR and DME, and possible 
reasons for difficulties in measuring HRQoL specifically for DME. Methods: We 
performed a literature review on articles describing instruments of patient-reported 
outcomes (PRO) for DME. We summarized the current evidence on the usefulness of 
the instruments and whether they differentiate between DR and DME. In addition, 
we investigated possible hurdles in measuring HRQoL for DME, given the clinical 
understandings of the systemic aspects of DME. Results: We identified seven con-
dition-specific or vision-specific measurements and seven general measurements 
including generic HRQoL and utilities for possible instruments for DME. However, 
realistic use for DME appears questionable even for vision-related measurements. 
The possible reasons could be that: 1) DME is not the primary disease, 2) many of 
DME patients have comorbidities such as DR, cataracts, and DR-induced glaucoma, 
and 3) those comorbidities itself may lead to decreased visual acuity with decreased 
HRQoL. ConClusions: Evidence is limited when measuring the impacts of DME 
on diabetic patients largely due to the lack of an effective PRO instrument for DME. 
The major difficulties in developing such instruments is that DME patients have 
complex health statuses, which provides for multiple reasons in decrease of QoL 
which may not be directly due to their DME.
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objeCtives: The Behavior Rating Inventory of Executive Function Preschool Version 
(BRIEF-P) was designed to provide a better understanding of preschool children’s self-
control and problem-solving skills. It is composed of 63 items organized in five clinical 
scales which measure five aspects of executive functioning (Inhibit, Shift, Emotional 
Control, Working Memory, Plan/Organize). It is used to evaluate children aged 2-5 years 
old with a wide spectrum of developmental and acquired neurological conditions, such 
as learning disabilities, Tourette’s disorder, traumatic brain injury, attention-deficit/
hyperactivity disorder or pervasive developmental disorders/autism. The objective of 
this study was to develop the BRIEF-P in 10 languages (Afrikaans, Bulgarian, Estonian, 
Greek, Japanese, Lithuanian, Romanian, Serbian, Slovak, Ukrainian). Methods: The 
following methodology was used: (1) Clarification of concepts with the developers; (2) 
Forward and backward translation steps in each target country. Results: The transla-
tion process did not reveal any cultural issues since most of the concepts assessed 
were cross-culturally relevant. The main difficulties consisted in finding conceptual 
equivalents of the original items with strong idiomatic content or containing words 
pertaining to the same semantic field. For instance, the most problematic items were 
items 10, 23 and 50. Item 23 (Is fidgety, restless, or squirmy) raised difficulties since it was 
not always possible to find direct equivalents for all adjectives in all languages. As 
for item 50 [Acts overwhelmed or overstimulated in crowded, busy situations (such as lots of 
noise, activity, or people)], discussions focused on how to convey the differences between 
“overwhelmed” and “overstimulated”, as well as between “busy” and “crowded.” 
In all cases, issues were solved with repeated discussions with the develop-
ers. ConClusions: The cross-cultural adaptation of the BRIEF-P into 10 languages 
required an international collaboration. The involvement of the developers during 
the whole process enabled the production of conceptually equivalent and culturally 
appropriate measures.
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objeCtives: Observer and Patient Itch-reported Outcome Instruments (ItchRO) 
are electronic morning and evening diaries developed in US English to assess itch-
related symptom severity (rubbing, scratching, skin damage, sleep disturbances or 
irritability) in pediatric patients suffering from rare cholestatic liver diseases such 
as Alagille Syndrome (ALGS). Itching is a key symptom in ALGS and significantly 
impacts on a child’s daily life. This research presents the recruitment challenges 
faced during the linguistic validation of the ItchRO into French, German, Polish and 
Spanish in ALGS patients. Methods: Native translators performed two forward and 
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selected for the development of mapping algorithms. The linear regression model 
had best model fit. However, the SEM that incorporated item level data for ordinal 
responses to each instrument showed better predictive performance, especially at 
the lower end of the EQ-5D distribution. ConClusions: This study demonstrates 
the flexibility of SEMs for the development of mapping algorithms. The models 
developed showed comparable predictive performance to existing models in the 
published literature.
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objeCtives: Network Meta-Analysis (NMA) is becoming a key component of sub-
missions to reimbursement agencies world-wide, especially when there is limited 
head-to-head evidence for multiple technologies. However, almost all NMAs only 
consider Randomised Controlled Trials (RCTs) even though there may be consid-
erable Real World Evidence (RWE) available – for example observational studies 
or registry-based studies. Evaluation of methods to enable the inclusion of RWE, 
especially in the light of the changing nature of RCTs from both a regulatory and 
reimbursement perspective, is considered here. Methods: RCTs and RWE stud-
ies were searched for using standard filters and databases up to, and including, 
the regulatory approval of Fingolimod by the European Medicines Agency (EMA) in 
2011 for Multiple Sclerosis (MS). A number of NMAs were then conducted and which 
included; only RCTs, both RCTs and RWE (accepted at face-value), both RCTs and 
RWE but including an additional level in the NMA hierarchical model to represent 
the different study designs, and finally both RCTs and RWE but adjusting the RWE 
for potential biases. Results: Identification of RWE in addition to RCTs in this 
MS example significantly increased the number of studies (and comparisons) that 
were potentially included in the NMA. Whilst the inclusion of the additional RWE 
led to a reduction in the level of uncertainty surrounding most effect estimates, 
this depended on the method of inclusion adopted for the RWE, and the extent to 
which biases were adjusted for. ConClusions: This initial evaluation of methods 
for the inclusion of RWE in NMAs indicates that methods of adjustment for the 
potential biases in RWE can have a significant impact on the level of uncertainty. 
Consequently further work investigating both empirical evidence for such biases 
and methods of elicitation from experts on the extent of biases associated with 
individual RWE studies is warranted.
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objeCtives: In meta-analysis, model selection is an important criterion which 
needs to be tested and validated by strong statistical evidence. The Cohran’s Q-test 
allows in theory to decide between random-effect and fixed-effect models. Due 
to the highly conservative nature of this test, three statistics have been built to 
estimate the heterogeneity between studies to lead the model decision: the I2, the 
H2 and the R2. We conducted a review of the Q-test utility in diverse scenarios with 
a comparison of three different methods to estimate the heterogeneity between 
studies. Methods: Based on the global formulation of the Cochran’s Q-test, we 
proposed to analyse jointly the first error species and the second error species in 
different scenarios based on the number of studies included in each meta-analysis. 
The goal was to determine the reliability of the Q-test in extreme situations but also 
to give some benchmark for the reliability of this test. We use simulation methods 
to analyse the three different methods for calculating the between-study variance 
compared to the real value of heterogeneity. We also compared different arbitrary 
levels for model selection using these statistics in different scenarios. Results: The 
Cochran’s Q-test is too conservative with a large number of studies and concludes to 
the presence of heterogeneity whatever the situation is when the number of studies 
is higher than 18. In comparison, the different statistics have an average value con-
versely linked with the number of studies in case of non-heterogeneity: the higher 
the number of studies, the lower the statistics’ average values. ConClusions: The 
I2 and H2statistics can eventually enhance the use of Cochran’s Q-test by solving 
conservative issue associated with this test. The model selection can, eventually, be 
led by benchmark of these statistics jointly with the Cochran’s Q-test.
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objeCtives: Indirect comparisons are increasingly accepted to model the clini-
cal- and cost-effectiveness of treatments. The purpose of this study was to (i) 
assess the literature reporting on the use of novel statistical methods [simulated 
treatment comparison (STC), and matching-adjusted indirect comparison (MAIC)]; 
and (ii) assess technology appraisals (TAs) submitted to the National Institute of 
Health and Carel Excellence (NICE) to determine whether these techniques have 
been accepted by reimbursement authorities. Methods: Embase, Medline and 
the Cochrane Library were interrogated to identify publications reporting on the 
use of MAIC or STC. NICE TAs published from 2011-2014 which reported MAIC or 
STC analyses were identified and the critique by the appraisal group was summa-
rised. Results: Six publications reported on the use of MAIC in six indications. 
Results from these analyses concluded that MAIC offered several advantages over 
conventional meta-analysis methods that rely on aggregate data. Findings from the 
review of NICE TAs indicated that these novel statistical techniques have not been 
objeCtives: Patient preferences have implications for treatment decision mak-
ing, treatment adherence and follow-up care. This study aimed to highlight, using 
metastatic breast cancer (mBC) as an example, a method to elicit preferences and, of 
particular novelty, examine individual differences of those preferences. Methods: 
Using mixed methods, a qualitative study (n= 10) of patients with mBC informed 
the development of the preference survey (a cross-sectional Internet survey admin-
istered to women with mBC). Survey participants (N= 181) completed a conjoint 
exercise that included a series of choice questions. Each choice question included a 
pair of hypothetical treatments that were presented in terms of eight safety attrib-
utes, single attributes for effectiveness, dosing regimen, and quality of life. Survey 
choice data were analyzed using hierarchical Bayesian logistic regression models. 
Predicted values from this model were then analyzed to understand individual 
differences in patient preference. Results: Qualitative interviews identified the 
most relevant side effects to include in the choice task (e.g., alopecia, nausea/vomit-
ing, etc.) and reinforced the importance of quality of life when making treatment 
decisions. In the survey data, treatment effectiveness was most strongly associated 
with treatment preference, followed by alopecia, fatigue, neutropenia, and quality 
of life. Predicted values from the choice model enabled preference comparisons 
across treatment experience subgroups (e.g., 6+ rounds of chemotherapy vs. less). 
Preference strength for individual attributes, e.g., side effects was correlated with 
various demographic and health history variables, though only modest associations 
were detected (Pearson rs< 0.25). ConClusions: Understanding patient prefer-
ences provides opportunities for improved care and outcomes. Combining qualita-
tive and quantitative methods in this study allowed for specificity of preferences 
and generalizability (albeit limited). Patient preferences derived across the sample 
informed predicted values from the choice models that can also be used for compar-
ing preferences across subsamples and identifying factors that may be associated 
with certain preferences.
ReseaRCH on MetHods – statistiCal MetHods
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objeCtives: Real-world (observational) data has the potential to address the limita-
tions of randomised controlled trials (RCTs) but presents its own challenges given 
the increased risk of bias. We compared the costs and quality-adjusted life years 
(QALYs) of patients following random vs preference-based allocation and assessed 
the performance of different methods to address these challenges. Methods: The 
REFLUX study was a pragmatic trial in patients with chronic reflux comparing lapa-
roscopic fundoplication (surgery) with medical management (MM) over 5 years of 
follow-up. The trial included randomised and non-randomised preference-based 
allocation. We compared the cost-effectiveness of surgery in the RCT vs preference 
cohorts as unadjusted raw differences, applying methods to handle biases from 
selection and confounding (regression adjustment, propensity score matching and 
instrument variable analysis) and explored the impact of receiving the preferred 
treatment on the results. Results: The preference surgery group accrued greater 
costs and QALYs than the randomised surgery group (£3,524 vs £2,852; 3.723 vs 
3.612 QALYs). The preference MM group had lower costs but slightly better QALYs 
than the randomised MM group (£861 vs £1,415; 3.541 vs 3.411 QALYs). The incre-
mental cost-effectiveness ratio (ICER) for the preference cohorts was similar to 
that obtained in the RCT using the different methods at around £8,000 per QALY 
gained (vs £7,149 in the RCT and £14,632 unadjusted raw differences). Receiving the 
preferred treatment was significantly associated with lower costs and better QALYs 
after adjusting for prognostic variables. ConClusions: Real-word data can be used 
in cost-effectiveness analysis to complement RCT evidence. However, more research 
is needed on how to choose the most appropriate method to adjust for selection 
bias and how to account for patient preferences when making recommendations 
on value for money.
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objeCtives: Mapping enables the prediction of health-state utility values via health 
outcome measures in trial data using algorithms linking those measures available 
to preference-based measures (PBMs). However, the unusual distributional features 
of PBMs mean that there is no consensus around the most appropriate statistical 
methodology for obtaining mapping algorithms. Existing studies have shown that 
structural equation modelling (SEM) developments open up a range of opportunities 
for effectively analysing PBMs. This study draws upon some of the methodological 
advances around SEMs from other fields in a case study. Progress towards develop-
ing a mapping algorithm for prediction of EQ-5D scores using a disease-specific 
measure, the Seattle Angina Questionnaire (SAQ), is discussed. Methods: EQ-5D 
and SAQ data were obtained from a completed RCT, the RITA-3 trial. Several psycho-
metric analysis approaches were considered to decide which subscales and items of 
the SAQ were likely to be relevant to the model. Several SEMs were specified and the 
first looked at the EQ-5D index values and SAQ subscales as continuous responses in 
a linear regression model. External information about the reliability of the disease-
specific measure was incorporated into this model. The subsequent models looked 
at the specification of outcomes at the item level with an ordinal logistic approach. 
Models were compared in terms of their ability to fit the observed data and their 
predictive performance. Results: Only three of the five subscales of the SAQ were 
